Cargando…

Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient

Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napolitano, Martina, Trudu, Lucia, Bertolini, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787422/ https://www.ncbi.nlm.nih.gov/pubmed/31607888 http://dx.doi.org/10.1159/000502858

Ejemplares similares

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation
por: Dong, Xiaopei, et al.
Publicado: (2021)

Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors
por: Frías, Aida, et al.
Publicado: (2023)

Serological identification of fast progressors of structural damage with rheumatoid arthritis
por: Siebuhr, Anne Sofie, et al.
Publicado: (2013)

Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases
por: Houessinon, Aline, et al.
Publicado: (2020)

Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report
por: Endo, Masashi, et al.
Publicado: (2023)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Tinnitus With Unexpected Spanish Roots: Head and Neck Paragangliomas Caused by SDHAF2 Mutation
por: Roose, Laura Maria, et al.
Publicado: (2020)

HIV-specific T-cell Responses and Generalized Activation in HIV-1 Infected Long-term Non-progressors and Progressors from South India
por: Swathirajan, Chinnambedu Ravichandran, et al.
Publicado: (2018)

Cardiac arrest due to an unexpected acute myocardial infarction during head and neck surgery: A case report
por: Kim, Jimin, et al.
Publicado: (2018)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
por: Botticelli, Andrea, et al.
Publicado: (2020)

Closing the inequality gaps in reproductive, maternal, newborn and child health coverage: slow and fast progressors
por: Amouzou, Agbessi, et al.
Publicado: (2020)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Minohara, Kiyoshi, et al.
Publicado: (2021)

Are Long-Term Non-Progressors Very Slow Progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988–2010
por: Mandalia, Sundhiya, et al.
Publicado: (2012)

Viral Reservoirs in Lymph Nodes of FIV-Infected Progressor and Long-Term Non-Progressor Cats during the Asymptomatic Phase
por: Eckstrand, C. D., et al.
Publicado: (2016)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Array Comparative Genomic Hybridization in Ulcerative Colitis Neoplasia: Single Non-Dysplastic Biopsies Distinguish Progressors from Non-Progressors
por: Bronner, Mary P., et al.
Publicado: (2010)

Factors associated with conversion of long-term non-progressors to progressors: A prospective study of HIV perinatally infected paediatric survivors
por: Radhakrishna, Muttineni, et al.
Publicado: (2013)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis
por: FRIIS-OTTESSEN, MARIANN, et al.
Publicado: (2015)

Pilomatrixoma in the head and neck
por: Neto, José Arruda Mendes, et al.
Publicado: (2015)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

Percentage of progressors in imaging: can we ignore regressors?
por: Sepriano, Alexandre, et al.
Publicado: (2019)

Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
por: Olson, Ashley D., et al.
Publicado: (2014)

Long term non-progressor (LTNP) HIV infection
por: Kumar, Praveen
Publicado: (2013)

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
por: Pareek, Ananya, et al.
Publicado: (2021)

Xanthogranuloma in the heavily irradiated low neck in a patient with head and neck cancer
por: Singer, Lisa, et al.
Publicado: (2016)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Extending the stroke treatment window beyond DAWN in patients with very slow progressor type collaterals: How far can we go?
por: Pagiola, Igor, et al.
Publicado: (2021)

Nivolumab‐induced sialadenitis
por: Takahashi, Saeko, et al.
Publicado: (2018)

Atypical Fibroxanthoma in Head and Neck
por: Kim, Jin Pyeong, et al.
Publicado: (2014)

Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
por: Ota, Takahiro, et al.
Publicado: (2019)

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
por: Higuchi, Mitsunori, et al.
Publicado: (2016)

“Lazarus response” of nivolumab in a frail patient with non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2017)

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer
por: Jun, Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ubq0c4iqtr02ob70v8gm0ph88